Dermira Wins First FDA Approval, Preps Qbrexza For October Launch In Hyperhidrosis

The company shifted attention in March from its big acne setback to its mid-year Qbrexza approval, so with a recent FDA nod for the hyperhidrosis treatment, Dermira will fill out its sales team and make the topical product for excessive underarm sweating available in October.

Diagnosis - Hyperhidrosis. Medical Concept with Blurred Text, Stethoscope, Pills and Syringe on Green Background. Selective Focus. 3D Render.

Dermira Inc. claimed an important victory when it won US FDA approval for Qbrexza (glycopyrronium) – a topical anticholinergic delivered by a cloth wipe – on June 29 for the treatment of primary axillary hyperhidrosis (excessive underarm sweating) in patients aged 9 and older.

The agency's decision marks the company's first-ever drug approval and it provided the Menlo Park, Calif., company with a needed...